Falnidamol

TargetMol
Product Code: TAR-TQ0271
Supplier: TargetMol
CodeSizePrice
TAR-TQ0271-1mg1mg£103.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-TQ0271-1mL1 mL * 10 mM (in DMSO)£148.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-TQ0271-5mg5mg£148.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-TQ0271-10mg10mg£209.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-TQ0271-25mg25mg£341.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-TQ0271-50mg50mg£544.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-TQ0271-100mg100mg£722.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT

Overview

Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃

Images

1 / 1

Further Information

Bioactivity:
Falnidamol (BIBX 1382) is a selective and orally active inhibitor of EGFR tyrosine kinase (IC50: 3 nM).
CAS:
196612-93-8
Formula:
C18H19ClFN7
Molecular Weight:
387.85
Pathway:
Angiogenesis; Tyrosine Kinase/Adaptors; JAK/STAT signaling
Purity:
0.98
SMILES:
CN1CCC(CC1)Nc1ncc2ncnc(Nc3ccc(F)c(Cl)c3)c2n1
Target:
EGFR

References

Dittrich Ch, et al. Phase I and pharmacokinetic study of BIBX 1382 BS, an epidermal growth factor receptor (EGFR) inhibitor, given in a continuous daily oral administration. Eur J Cancer. 2002 May;38(8):1072-80. Solca FF, et al. Inhibition of epidermal growth factor receptor activity by two pyrimidopyrimidine derivatives. J Pharmacol Exp Ther. 2004 Nov;311(2):502-9.